טבע, Amazon Web Services ו- Onica מודיעות על שיתוף פעולה לתמיכה בפורטפוליו ®Digihaler של טבע

פורטפוליו מוצרי הנשימה הדיגיטליים של טבע מתוחזק כעת על ידי AWS

21 אוק 2020 | זמן קריאה ממוצע: 2 דקות

תל אביב וסן אנטוניו, טקסס, 21 באוקטובר 2020 - טבע נשימה בע"מ, חברה בת של טבע תעשיות פרמצבטיות בע"מ (NYSE  ו- TASE: TEVA), הודיעה היום כי החברה משתפת פעולה עם Web Services, Inc. Amazon ו- Onica, חברה של Rackspace Technology, לבנות ולארח את פלטפורמת הבריאות הדיגיטלית שלה.

פלטפורמת הבריאות הדיגיטלית של טבע הינה מערכת נתוני backend מבוססת ענן התומכת כיום בפורטפוליו מוצרי ®Digihaler שאושר על ידי ה- FDA, המשפחה הראשונה אי פעם של משאפים דיגיטליים, המופעלים באמצעות נשימה, המכילים חיישנים מובנים וטכנולוגיית ®Bluetooth אלחוטי, המתחברת לאפליקציה סלולרית נלווית העוקבת אחר השימוש במשאף ומודדת זרימה נשימתית כאשר המטופל שואף.

הטכנולוגיה, כמו משפחת המשאפים של ®Digihaler, מספקת נתוני אירועי משאף אובייקטיביים אשר עשויים לסייע בטיפוח דיאלוג בין מטופלים ונותני שירותי בריאות (HCP) ולעזור לקבלת החלטות טיפוליות. מכשיר ®Digihaler מזהה, רושם ומאחסן באופן אוטומטי נתוני אירועי שאיפה ומודד קצב זרימה נשימתי.

" Onica מובילה כמה מהפרויקטים הטכנולוגיים המורכבים ביותר בעולם", אמרה טולגה טרהאן, CTO, Rackspace Technology. "אנו ממוקמים בצומת הבריאות והטכנולוגיה. באמצעות השותפות שלנו עם טבע, אנו עומדים לחולל מהפכה בדרך בה המטופלים ניגשים לנתונים שלהם. נגישות ואבטחה הם בחזית השירותים שלנו ואנחנו גאים לעבוד על פלטפורמת הבריאות הדיגיטלית של טבע."

צוות הפיתוח של Onica תמך בבניית פלטפורמת הבריאות הדיגיטלית של טבע ללא שרתים, מה שמאפשר למערכת למנף באופן מלא את יכולות הענן הטובות ביותר של AWS. אירוח פלטפורמת הבריאות הדיגיטלית של טבע ב- AWS יאפשר מינוף יתרון לגודל, גמישות וחסכוניות.

"אנו שמחים לאחד את תיק השירותים ללא תחרות של AWS עם המוניטין והנסיון של טבע בתחום הנשימה כדי לספק כעת נתוני שימוש אובייקטיביים במשאפים אשר עשויים לסייע ליידע את הרופאים בטיפול בחולים", אמר ד"ר שז פרטובי, מנהל פיתוח עסקי עולמי בתחום הבריאות, מדעי החיים וגנומיקה ב- AWS. "הגישה של טבע לספק למטופלים נגישות ושליטה בשיתוף נתוני אירועי המשאף שלהם עם רופאיהם עשויה להשפיע ​​על אופן הטיפול בחולים, ובפרט במחלת אסתמה ומחלת ריאות כרונית (COPD).”

עם מערכת ענן זו במקום, המשתמשים יוכלו להציג מידע מאוחסן על אירועי ה- ®Digihaler שלהם באמצעות האפליקציה הניידת הנלווית, שניתן לקשר למכשירי משאף מרובים. חולים יכולים לבדוק את הנתונים שלהם לאורך זמן, לקבל התראות על אירועים, כולל אם טכניקת השאיפה שלהם עשויה להזדקק לשיפור. אם תרצה, ניתן לשתף מידע זה עם ספקי שירותי הבריאות שלהם כדי לקיים דיונים מושכלים יותר על מצבם וטיפולם.

"מכיוון שמוצרי ®Digihaler שלנו זמינים כעת מסחרית למטופלים, הבטחת אבטחת הנתונים היא החשובה ביותר", אמר סוון דטלפס, סגן נשיא בכיר, פורטפוליו ושיווק גלובלי בטבע. "עם בריאות דיגיטלית וניטור מרחוק המהווים אלמנטים חיוניים בטיפול בחולים, אנו שמחים לעבוד עם AWS ו- Onica, המנוסות בלהבטיח שהמידע של המטופלים מאובטח ונגיש בקלות עבורם."

The Digihaler® portfolio currently includes ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder, which is indicated for use in patients 4 years of age and older to treat or prevent bronchospasm in those who have reversible obstructive airway disease and to prevent exercise-induced bronchospasm, in addition to AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder, both indicated for the maintenance treatment of asthma in patients 12 years of age and older. All three products are approved by the U.S. Food and Drug Administration (FDA) and are commercially available to patients by prescription. Please view the complete indications and Important Safety Information for these products below.

PROAIR® DIGIHALER® APPROVED USES

ProAir® Digihaler® (albuterol sulfate) Inhalation Powder is a prescription medicine used in people 4 years of age and older to:

  • treat or prevent bronchospasm in people who have reversible obstructive airway disease
  • prevent exercise-induced bronchospasm

ProAir Digihaler contains a built-in electronic module that detects, records and stores inhaler event information. ProAir Digihaler may be used with, and transmits information to, a mobile app. ProAir Digihaler does not need to be connected to the mobile app in order for you to take your medicine.

proair® digihaler® IMPORTANT SAFETY INFORMATION

  • Do not use ProAir Digihaler (albuterol sulfate) Inhalation Powder if you are allergic to albuterol sulfate, lactose, milk proteins, or any of the ingredients in ProAir Digihaler. Ask your healthcare provider if you have any questions or are not sure
  • Before using ProAir Digihaler, tell your healthcare provider about all of your medical conditions, including if you:
    • have heart problems
    • have high blood pressure (hypertension)
    • have convulsions (seizures)
    • have thyroid problems
    • have diabetes
    • have low potassium levels in your blood
    • are pregnant or planning to become pregnant
    • are breastfeeding or planning to breastfeed
  • Tell your healthcare provider about all the medicines you take, especially:
    • other inhaled medicines or asthma medicines
    • beta blocker medicines
    • diuretics
    • digoxin
    • monoamine oxidase inhibitors
    • tricyclic antidepressants
  • Do not increase your dose or take extra doses of ProAir Digihaler without first talking to your healthcare provider
  • Get medical help right away if ProAir Digihaler no longer helps your symptoms, your symptoms get worse or you need to use your inhaler more often
  • While you are using ProAir Digihaler, do not use other inhaled rescue medicines and asthma medicines unless your healthcare provider tells you to do so
  • ProAir Digihaler may cause serious side effects, including:
    • worsening trouble breathing, coughing and wheezing (paradoxical bronchospasm). If this happens, stop using ProAir Digihaler and call your healthcare provider or get emergency help right away. This is more likely to happen with your first use of a new asthma inhalation medicine
    • heart problems, including faster heart rate and higher blood pressure
    • possible death in people with asthma who use too much ProAir Digihaler
    • allergic reactions. Call your healthcare provider right away if you have the following symptoms of an allergic reaction:
      • itchy skin
      • swelling beneath your skin or in your throat
      • rash
      • worsening trouble breathing
    • changes in laboratory blood values (sugar, potassium)
  • The most common side effects of ProAir Digihaler include:
    • back pain
    • body aches and pain
    • upset stomach
    • sinus headache
    • urinary tract infection
    • your heart feels like it is pounding or racing (palpitations)
    • chest pain
    • fast heart rate
    • shakiness
    • nervousness
    • headache
    • dizziness
    • sore throat
    • runny nose
  • These are not all of the possible side effects of ProAir Digihaler. For more information, ask your healthcare provider or pharmacist
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088


Please read the full Prescribing Information.

APPROVED USES AND IMPORTANT SAFETY INFORMATION FOR AIRDUO® DIGIHALER® AND ARMONAIR® DIGIHALER®

APPROVED USES

  • AIRDUO® DIGIHALER® (fluticasone propionate and salmeterol) inhalation powder is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older.
  • ARMONAIR® DIGIHALER® (fluticasone propionate) inhalation powder is a prescription medicine for the long-term treatment of asthma in patients 12 years and older.
  • AIRDUO DIGIHALER and ARMONAIR DIGIHALER are not used to relieve sudden breathing problems from asthma and won't replace a rescue inhaler.

AIRDUO DIGIHALER  and ARMONAIR DIGIHALER  each contain a built-in electronic module that records and stores information about inhaler events. AIRDUO DIGIHALER  and ARMONAIR DIGIHALER  may be used with, and transmit information to, a mobile App. AIRDUO DIGIHALER  and ARMONAIR DIGIHALER do not need to be connected to the app in order for you to take your medicine.

IMPORTANT SAFETY INFORMATION

  • AIRDUO DIGIHALER contains salmeterol. Long-acting beta2-agonist (LABA) medicines such as salmeterol when used alone increase the risk of hospitalizations and death from asthma problems. AIRDUO DIGIHALER contains an inhaled corticosteroid (ICS) and a LABA. When an ICS and a LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems.
  • Do not use AIRDUO DIGIHALER or ARMONAIR DIGIHALER to treat sudden breathing problems from asthma. Always have a rescue inhaler with you to treat sudden symptoms.
  • Do not use AIRDUO DIGIHALER or ARMONAIR DIGIHALER if you have a severe allergy to milk proteins or if you are allergic to any of the ingredients in the product. Ask your healthcare provider if you are not sure.
  • Do not use AIRDUO DIGIHALER or ARMONAIR DIGIHALER more often than prescribed.
  • Do not take AIRDUO DIGIHALER with other medicines that contain a LABA for any reason.
  • Tell your healthcare provider about all the medicines you take and about all of your health conditions.
  • Do not stop using ARMONAIR DIGIHALER, even if you are feeling better, unless your healthcare provider tells you to. If you miss a dose of ARMONAIR DIGIHALER, just skip that dose. Take your next dose at your usual time. Do not take 2 doses at 1 time.
  • AIRDUO DIGIHALER and ARMONAIR DIGIHALER can cause serious side effects, including:
    • Fungal infection in your mouth or throat (thrush). Rinse your mouth with water without swallowing after using AIRDUO DIGIHALER or ARMONAIR DIGIHALER to help reduce your chance of getting thrush.
    • Weakened immune system and increased chance of getting infections (immunosuppression). You should avoid exposure to chickenpox and measles, and, if exposed, tell your healthcare provider right away. Worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or herpes infection of the eye (ocular herpes simplex) may occur.
    • Reduced adrenal function. This can happen when you stop taking an oral corticosteroid (such as prednisone) and start taking a medicine containing an ICS (such as AIRDUO DIGIHALER or ARMONAIR DIGIHALER). During this transition period, when your body is under stress such as from fever, trauma (such as a car accident), infection, or surgery, adrenal insufficiency can get worse and may cause death. Symptoms of adrenal insufficiency include:
      • feeling tired
      • lack of energy
      • Weakness
      • nausea and vomiting
      • low blood pressure
  • For AIRDUO DIGIHALER, there may be sudden breathing problems immediately after inhaling your medicine. If you have sudden breathing problems immediately after inhaling your medicine, stop using AIRDUO DIGIHALER and call your healthcare provider right away.
  • Serious allergic reactions. Stop using AIRDUO DIGIHALER or ARMONAIR DIGIHALER and call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction:
    • rash
    • hives
    • swelling of your face, mouth, and tongue
    • breathing problems
  • AIRDUO DIGIHALER can also cause additional serious side effects, including:
    • Effects on the heart
      • increased blood pressure
      • a fast or irregular heartbeat
      • chest pain
    • Effects on the nervous system
      • Tremor
      • nervousness
  • AIRDUO DIGIHALER and ARMONAIR DIGIHALER can cause:
    • Bone thinning or weakness (osteoporosis)
    • Slowed growth in children. A child's growth should be checked often.
    • Eye problems including glaucoma and cataracts. You should have regular eye exams while using AIRDUO DIGIHALER or ARMONAIR DIGIHALER.
  • For AIRDUO DIGIHALER, changes may occur in laboratory blood values (sugar, potassium, certain types of white blood cells)
  • For ARMONAIR DIGIHALER increased wheezing (bronchospasm) may occur. Increased wheezing can happen right away after using ARMONAIR DIGIHALER. If this occurs, stop using ARMONAIR DIGIHALER and call your healthcare provider. Always have a rescue inhaler with you to treat sudden wheezing.
  • Common side effects of AIRDUO DIGIHALER and ARMONAIR DIGIHALER include:
    • thrush in your mouth or throat. Rinse your mouth with water without swallowing after use to help prevent this.
    • Headache
    • cough
  • Additionally, AIRDUO DIGIHALER has common side effects of:
    • back pain
    • infection of nose and throat (nasopharyngitis)
  • ARMONAIR DIGIHALER has common side effects of:
    • upper respiratory tract infection
    • infection or inflammation of nose and throat (nasopharyngitis)

 

  • These are not all the possible side effects of AIRDUO DIGIHALER and ARMONAIR DIGIHALER. Call your healthcare provider for medical advice about side effects.

  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch, or call 1-800-FDA-1088.

 

Please see full Prescribing Information for AIRDUO DIGIHALER and ARMONAIR DIGIHALER.

אודות טבע

טבע תעשיות פרמצבטיות בע"מ (NYSE & TASE: TEVA) מפתחת ומייצרת תרופות לשיפור חייהם של אנשים מזה למעלה ממאה שנה. אנו מובילים גלובליים בגנריקה ובתרופות ייחודיות, עם פורטפוליו הכולל יותר מ- 3,500 מוצרים בכמעט כל תחום טיפולי. בכל יום, קרוב ל-200 מיליון אנשים ברחבי העולם נוטלים תרופה של טבע, הודות לאחת ממערכות התפעול הגדולות והמורכבות בתעשייה הפרמצבטית. נוסף על מעמדנו המבוסס בגנריקה, יש לנו פעילות מחקר חדשני משמעותית התומכת בפורטפוליו המוצרים הייחודיים והביופרמצבטיים הגדל שלנו. למידע נוסף על החברה, בקרו באתר www.Teva.co.il

Cautionary Note Regarding Forward-Looking Statements

This Press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Teva’s digital health platform supporting our Digihaler® portfolio which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

  • the commercial success of our Digihaler family of inhalers;
  • our ability to achieve the expected benefits from our digital health platform;
  • our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally-administered alternatives; the uncertainty of commercial success of AJOVY® or AUSTEDO®; competition from companies with greater resources and capabilities; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; ability to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations and the effectiveness of our patents and other measures to protect our intellectual property rights;
  • our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
  • our business and operations in general, including: uncertainty regarding the magnitude, duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our restructuring plan announced in December 2017; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our suppliers; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; our prospects and opportunities for growth if we sell assets; and potential difficulties related to the operation of our new global enterprise resource planning (ERP) system;
  • compliance, regulatory and litigation matters, including: our ability to successfully defend against the DOJ criminal charges of a Sherman Act violations; increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S. and our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time due to modified government operations due to the COVID-19 pandemic, including effects on product and patent approvals due to the COVID-19 pandemic; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into S&M practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
  • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Quarterly Reports on Form 10-Q for the first and second quarters of 2020 and in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

About Onica, a Rackspace Technology Company

Onica is a global cloud native services provider at the forefront of cloud computing. As an Amazon Web Services (AWS) APN Premier Consulting Partner and audited Managed Services Provider, we help our customers solve the most complex and transformative cloud projects in the world to build new revenue streams, increase efficiency, and deliver incredible experiences. 

As a Rackspace Technology Company, we are backed by a global network of experts delivering proven solutions across the full spectrum of cloud technology. Everything we do is wrapped in our obsession with our customers’ success – our Fanatical Experience™ – so they can work faster, smarter, and stay ahead of what’s next.

כתבות נוספות בנושא